Jupiros-A 150 Capsule is a combination pharmaceutical formulation containing Rosuvastatin 10 mg and Aspirin 150 mg, designed for the management of cardiovascular conditions. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerosis and related cardiovascular events. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent inhibition of platelet aggregation, which helps prevent thrombus formation. The combined action of these agents provides synergistic benefits in the primary and secondary prevention of cardiovascular diseases, including myocardial infarction, stroke, and peripheral arterial disease. Jupiros-A 150 is indicated for patients at high risk of cardiovascular events who require both lipid-lowering therapy and antiplatelet prophylaxis. It should be used under medical supervision, with caution in patients with bleeding disorders, hepatic or renal impairment, and those on concomitant anticoagulant therapy. Regular monitoring of lipid profiles, liver enzymes, and platelet function is recommended to ensure therapeutic efficacy and safety. Adherence to prescribed dosage and lifestyle modifications enhances clinical outcomes with Jupiros-A 150 Capsule.